Show simple item record

Antiviral drugs in the prophylaxis of HBV infection

dc.contributor.authorMasgala, Aikaterinien
dc.contributor.authorNikolopoulos, Georgios K.en
dc.contributor.authorTsiodras, Sotiriosen
dc.contributor.authorBonovas, Stefanosen
dc.contributor.authorSitaras, N. M.en
dc.creatorMasgala, Aikaterinien
dc.creatorNikolopoulos, Georgios K.en
dc.creatorTsiodras, Sotiriosen
dc.creatorBonovas, Stefanosen
dc.creatorSitaras, N. M.en
dc.date.accessioned2018-06-22T09:54:02Z
dc.date.available2018-06-22T09:54:02Z
dc.date.issued2012
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42155
dc.description.abstractReactivation of hepatitis B infection (HBV) is known to occur in liver graft recipients and in chronic carriers of the surface antigen of HBV who receive immunosuppressive therapy. The use of hepatitis B immune globulin alone or in combination with antiviral agents such as lamivudine, adefovir, tenofovir, entecavir, famciclovir, ganciclovir, as prophylaxis in HBV liver transplants, has been well documented. In terms of HBV positive carriers undergoing cytotoxic chemotherapy, the preemptive use of nucleoside or nucleotide analogues seems to be effective. Monotherapy or combination of antiviral drugs, as well as the optimal duration of HBV prophylaxis, is to be determined. © 2012 Bentham Science Publishers.en
dc.language.isoengen
dc.sourceCurrent medicinal chemistryen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectMonotherapyen
dc.subjectHematologic neoplasmsen
dc.subjectLamivudineen
dc.subjectSolid tumoren
dc.subjectUnclassified drugen
dc.subjectLiver neoplasmsen
dc.subjectCorticosteroiden
dc.subjectRituximaben
dc.subjectImmunosuppressionen
dc.subjectAnthracyclineen
dc.subjectAlemtuzumaben
dc.subjectDrug cytotoxicityen
dc.subjectAdefovir dipivoxilen
dc.subjectAntiviral agentsen
dc.subjectEntecaviren
dc.subjectHepatitis ben
dc.subjectHepatitis b virusen
dc.subjectTenofovir disoproxilen
dc.subjectAdefoviren
dc.subjectAntiviral drugsen
dc.subjectAntivirus agenten
dc.subjectCytovenen
dc.subjectDisease carrieren
dc.subjectDrug solubilityen
dc.subjectFamcicloviren
dc.subjectFoscarneten
dc.subjectGancicloviren
dc.subjectHbv infectionen
dc.subjectHepatitis b antibodyen
dc.subjectHepatitis b surface antigenen
dc.subjectImmunocompromised patienten
dc.subjectInfliximaben
dc.subjectInjection site painen
dc.subjectLiver transplantationen
dc.subjectNucleos(t)ide analoguesen
dc.subjectNucleotide derivativeen
dc.subjectProphylaxisen
dc.subjectReinfectionen
dc.subjectTenofoviren
dc.subjectVirus activationen
dc.subjectVirus reactivationen
dc.titleAntiviral drugs in the prophylaxis of HBV infectionen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2174/092986712804485980
dc.description.volume19
dc.description.issue35
dc.description.startingpage5940
dc.description.endingpage5946
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidNikolopoulos, Georgios K.[0000-0002-3307-0246]
dc.contributor.orcidBonovas, Stefanos [0000-0001-6102-6579]
dc.contributor.orcidTsiodras, Sotirios [0000-0002-0463-4321]
dc.gnosis.orcid0000-0002-3307-0246
dc.gnosis.orcid0000-0001-6102-6579
dc.gnosis.orcid0000-0002-0463-4321


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record